1 / 43

SMOKING CESSATION

SMOKING CESSATION. Leading Preventable Cause of Death 400,000 to 500,000 deaths per year in USA 3 Million deaths world wide 1 of every 6 deaths in USA Directly attributable to smoking Yet — 46 Million continue to smoke. SMOKING. “A cigarette is a finely tuned drug delivery system”

rinah-england
Télécharger la présentation

SMOKING CESSATION

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. SMOKING CESSATION • Leading Preventable Cause of Death • 400,000 to 500,000 deaths per year in USA • 3 Million deaths world wide • 1 of every 6 deaths in USA Directly attributable to smoking • Yet — 46 Million continue to smoke

  2. SMOKING “A cigarette is a finely tuned drug delivery system” Katherine E. Hartman, MD

  3. SMOKING “Smoking is not a bad habit --- It is a chronic medical condition” Michael C. Fiore, MD

  4. SMOKING CESSATION • Why do we smoke? • Why should we stop/benefits? • How do we stop?

  5. Nicotine Dependence slide “As an addictive substance, nicotine, on a milligram for milligram basis, is 10 times more potent than heroin…” Sachs DPL. Advances in Smoking Cessation Treatment In: Simmons, ed. Current Pulmonology, Chicago; Year Book Medical Publishers, 1991, 12:139-198

  6. SMOKING CESSATION Why Do We Smoke? 3-Pronged Dependency • Physiological • Psychological • Behavioral

  7. Why Do We Smoke? Physiological • Nicotine to brain – 7 seconds • Binds to nicotine receptors resulting in secretion of Dopamine • Causes a pleasurable sensation and cognitive arousal

  8. Physiological Increased Levels of: Norepinephrine Beta-Endorphin Acetylcholine Serotonin Glutamate Vasopressin

  9. Physiological • Enhance: • Concentration • Alertness • Memory • Decrease: • Tension • Anxiety Promotes feeling of well being

  10. SMOKING CESSATION Why should we stop smoking? Benefits: General Cardio-cerebrovascular Cancer Pulmonary

  11. SMOKING CESSATION • Long term tobacco use raises the risk of premature death by 50% * • Quitting at any age increases longevity • Those who quit smoking by age 50 decrease their risk of dying over the next 15 years by 50% compared with those who do not stop ** * W.H.O. Tobacco Dependency Fact Sheet #222 1999 ** U.S. Dept of Health & Human Services publication #90-8416

  12. SMOKING CESSATION Why should we stop smoking? Benefits: General Cardio-cerebrovascular Cancer Pulmonary

  13. Why should we stop smoking? • 30% of all Cancer Deaths related to Smoking • 4000 Chemicals in Tar • 43 Carcinogenic

  14. Why should we stop smoking? • Lung Cancer – Most Common in Cancer • Oral 9 fold increase • Throat 9 fold increase • Esophagus 75% in smokers • Bladder 7 fold increase • Kidney 5 fold increase • Pancreas 2 fold increase • Stomach 1.5 fold increase

  15. Why should we stop smoking? Lung Cancer • Life Long risk in Non-Smoker – 1% • 15-25% risk in heavy smokers • Each Cigarette cuts 6 minutes off of life

  16. SMOKING CESSATION Why should we stop smoking? Benefits: General Cardio-cerebrovascular Cancer Pulmonary

  17. How Do We Stop Smoking? Problems • Patient Motivation • Physician Interest • Medications • Support Systems

  18. SMOKING CESSATION Patient Motivation • 70% want to quit • 2 large studies • Appropriate moment

  19. SMOKING CESSATION The Right Moment Acute MI Intervention Minimal 55% 34% Dornelas, E.A. Prev Med 2000; 30, 216-228

  20. The Negatives • Physicians advising patients to stop 1975 – 38% 1983 – 42% 1991 – 48% • 1672 Ex-Smokers • 3.6% Physician Helped • 70% smokers see physician yearly

  21. SMOKING • 38 Family Practices • 2963 Smokers - Addressed in 21% • Increased to 58% if Doctor used standard forms for recording smoking status • When smokers identified • smoking cessation therapy started in only 38% • 68% of the offices had smoking cessation material J. Fam. Pract. 2001; 50: 688-9

  22. Physicians Role in Smoking Cessation The Positives • Admit Nicotine is an Addiction • Provide information • Show an interest • Train office personnel • Select the opportunity

  23. SMOKING CESSATION The 5 A’s Ask Advise Assess Assist Arrange

  24. Planning a Program • Establish degree of nicotine dependency • Serum Cotinine Level • Fagerstrom Test • Quit Date • Support Group • Behavioral Modification • Discuss Relapses & Weight Gain

  25. Pharmacologic • Nicotine Replacement • Bupropion

  26. Planning A Program • Low Dependency • Nicotine Replacement • High Dependency • Bupropion + • Nicotine Replacement x 2

  27. Nicotine Replacement N=504 Patch 21% Gum 20% Spray 24% Inhaler 24% Arch. Int. Med. September 27, 1999

  28. Nicotine Replacement Gum – 1984 • Disadvantages • Heartburn and Indigestion • Throat and Mouth Irritation • Sore Jaw • Flatulence • Advantages • Neutral PH • More Rapid • Adjunct

  29. Nicotine Replacement Patch – 1991 • Advantages • Convenient • Best Compliance • 30-40% while on patch • 10% at 1 year • Disadvantages • Skin Irritation • Over the counter

  30. Nicotine Replacement Nasal Spray • Advantages • Alone or Combination • Fast Acting - Urge • Disadvantages • Irritation • Low Compliance

  31. Nicotine Replacement Inhaler • Advantages • Hand-Mouth • Disadvantages • Low Compliance • Less Nicotine • Delivery

  32. Nicotine Replacement Lozenge – 2002

  33. Bupropion • Placebo 23% • Nicotine Replacement 36% • Bupropion 300 MA 49% • Bupropion + Nicotine 58% • Long Term 25-35%

  34. SMOKING CESSATION N12 MOKG • Placebo 160 15.6% 2.1 • Nicotine Patch 244 16.4% 1.6 • Bupropion 244 30.3% 1.7 • Bupropion + patch 245 35.5% 1.1 JORENBY - N.E.J.M. 3/4/99

  35. SMOKING CESSATION BUPROPION 450 Smokers (Failed Treatment) Again Placebo 27% 5% • Gonzales DH, Clin. Pharm Therapy 2001; 69

  36. SMOKING CESSATION BUPROPION Duration 784 PATIENTS 7 WEEKS TREATMENT PLACEBO 12 MONTHS 55% 42% • Hays, JT. Ann Intern Med. 2001 135

  37. SUMMARY • Smoking KILLS • Physicians can and should play a role in helping patients stop smoking • Effective tools are available and they work

  38. SUMMARY • Include Smoking as a Vital Sign • Use the 5 A’s • Use multiple modalities • Use them long enough • Be Persistent

More Related